Fostamatinib, also known as R 788 and R-935788, is an orally active, potent and selective Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib is also a pro-drug of R-406. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage.
Felfer, Ulfried; Giselbrecht, Karl-Heinz; Wolberg, Michael. Synthesis of N4-(2,2-dimethyl-4-[(dihydrogen phosphonoxy)-3-oxo-5-pyrido[1,4]oxazin-6-yl]-5-fluoro-N2-(3,4,5-trimethoxyphenyl))-2,4-pyrimidinediamine disodium salt. Assignee Rigel Pharmaceuticals, Inc., USA. WO 2011002999. (2011).
1. Grossbard, Elliott; Argade, Ankush; Singh, Rajinder; Hitoshi, Yasumichi. (Assignee Rigel Pharmaceuticals, Inc., USA). Preparation of pyrimidine-2,4-diamines as RET kinase inhibitors for treatment of cell proliferative disorders. WO 2009003136. 2. Argade, Ankush; Bhamidipati, Somasekhar; Li, Hui; Sylvain, Catherine; Clough, Jeffrey; Carroll, David; Keim, Holger; Braselmann, Sylvia; Taylor, Vanessa; Zhao, Haoran; Herlaar, Ellen; Issakani, Sarkiz D.; Wong, Brian R.; Masuda, Esteban S.; Payan, Donald G.; Singh, Rajinder. Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling. Bioorg. & Med. Chem. Lett. 2015, 25(10), 2122-2128
